X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (3499) 3499
humans (3024) 3024
animals (2385) 2385
tetrazoles - pharmacology (2148) 2148
female (1992) 1992
tetrazoles - administration & dosage (1888) 1888
tetrazoles - therapeutic use (1781) 1781
rats (1563) 1563
middle aged (1459) 1459
blood pressure - drug effects (1292) 1292
hypertension - drug therapy (1255) 1255
pharmacology & pharmacy (1212) 1212
aged (1185) 1185
hypertension (1083) 1083
valsartan (1014) 1014
adult (959) 959
treatment outcome (897) 897
peripheral vascular disease (870) 870
valine - analogs & derivatives (860) 860
angiotensin receptor antagonists (856) 856
antihypertensive agents - administration & dosage (792) 792
losartan (747) 747
antihypertensive agents - therapeutic use (738) 738
drug therapy, combination (738) 738
tetrazoles - adverse effects (732) 732
dose-response relationship, drug (713) 713
imidazoles - pharmacology (691) 691
biphenyl compounds - pharmacology (653) 653
cardiac & cardiovascular systems (632) 632
angiotensin (600) 600
rats, sprague-dawley (581) 581
double-blind method (578) 578
angiotensin ii type 1 receptor blockers - therapeutic use (573) 573
hypertension - physiopathology (556) 556
antihypertensive agents - pharmacology (551) 551
benzimidazoles - pharmacology (526) 526
time factors (515) 515
angiotensin ii type 1 receptor blockers - administration & dosage (483) 483
angiotensin ii type 1 receptor blockers - pharmacology (483) 483
biphenyl compounds - administration & dosage (478) 478
blood pressure (474) 474
tetrazoles - pharmacokinetics (463) 463
mice (446) 446
administration, oral (444) 444
blood-pressure (443) 443
benzimidazoles - administration & dosage (438) 438
valine - administration & dosage (433) 433
benzimidazoles - therapeutic use (419) 419
angiotensin ii (417) 417
biphenyl compounds - therapeutic use (416) 416
imidazoles - administration & dosage (406) 406
disease models, animal (398) 398
drug therapy (398) 398
cilostazol (385) 385
antihypertensive agents - adverse effects (380) 380
valine - therapeutic use (376) 376
rats, wistar (372) 372
candesartan (367) 367
imidazoles - therapeutic use (361) 361
heart failure - drug therapy (341) 341
prospective studies (340) 340
angiotensin ii - pharmacology (315) 315
irbesartan (309) 309
expression (307) 307
heart failure (302) 302
mortality (300) 300
analysis (298) 298
heart rate - drug effects (290) 290
renin-angiotensin system - drug effects (288) 288
research (288) 288
valine - pharmacology (279) 279
angiotensin ii - antagonists & inhibitors (277) 277
renin-angiotensin system (274) 274
pharmacokinetics (270) 270
aged, 80 and over (267) 267
double-blind (262) 262
medicine & public health (256) 256
pyridines - pharmacology (253) 253
drug combinations (251) 251
risk factors (249) 249
hydrochlorothiazide - administration & dosage (247) 247
internal medicine (246) 246
olmesartan medoxomil (245) 245
neurosciences (244) 244
angiotensin-converting enzyme inhibitors - therapeutic use (243) 243
dosage and administration (243) 243
inhibition (243) 243
physiology (241) 241
follow-up studies (236) 236
hypertension - complications (236) 236
oxidative stress (236) 236
rats, inbred shr (235) 235
prevention (233) 233
tetrazoles (233) 233
amlodipine (231) 231
angiotensin-ii (230) 230
angiotensin ii type 1 receptor blockers - adverse effects (224) 224
receptor, angiotensin, type 1 (223) 223
therapy (223) 223
hemodynamics - drug effects (221) 221
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4907) 4907
Japanese (113) 113
German (70) 70
Russian (33) 33
Chinese (24) 24
French (16) 16
Spanish (8) 8
Italian (4) 4
Ukrainian (4) 4
Danish (3) 3
Czech (2) 2
Hungarian (2) 2
Swedish (2) 2
Arabic (1) 1
Bulgarian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2016, Volume 374, Issue 21, pp. 2032 - 2043
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10073, pp. 1035 - 1042
Journal Article
European heart journal, ISSN 1522-9645, 2017, Volume 38, Issue 15, pp. 1132 - 1143
Background Compared to heart failure patients with higher systolic blood pressure (SBP), those with lower SBP have a worse prognosis. To make matters worse,... 
Heart failure | TRIAL | AT1-receptor | NEPRILYSIN INHIBITION | CARDIAC & CARDIOVASCULAR SYSTEMS | Angiotensin | Neprilysin | Blood pressure | ENALAPRIL | Valsartan - administration & dosage | Humans | Aminobutyrates - adverse effects | Male | Death, Sudden, Cardiac - etiology | Enalapril - adverse effects | Dose-Response Relationship, Drug | Hypotension - mortality | Tetrazoles - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Female | Blood Pressure - drug effects | Aminobutyrates - administration & dosage | Drug Therapy, Combination | Enalapril - administration & dosage | Heart Failure - mortality | Drug Administration Schedule | Stroke Volume - physiology | Valsartan - adverse effects | Treatment Outcome | Hospitalization | Hypotension - chemically induced | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Heart Failure - drug therapy | Neprilysin - antagonists & inhibitors | Aged | Tetrazoles - adverse effects | Chronic Disease | Angiotensin Receptor Antagonists - administration & dosage | Angiotensin Receptor Antagonists - adverse effects | Clinical Research | Editor's Choice | Kardiologi | Cardiac and Cardiovascular Systems | enalapril heart failure | chronic hypotension systolic blood pressure heart failure blood pressure cardiovascular system safety ejection fraction cardiovascular death sacubitril / valsartan
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 383, Issue 9932, pp. 1889 - 1898
Summary Background The fixed-dose combination of any two antihypertensive drugs from different drug classes is typically more effective in reducing blood... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | MONOTHERAPY | METAANALYSIS | BETA-BLOCKERS | TOLERABILITY | Benzopyrans - adverse effects | Ethanolamines - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzopyrans - therapeutic use | Valsartan | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Valine - administration & dosage | Ethanolamines - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Tetrazoles - administration & dosage | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Blood Pressure - drug effects | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - therapeutic use | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Nebivolol | Double-Blind Method | Drug Administration Schedule | Valine - analogs & derivatives | Treatment Outcome | Antihypertensive Agents - therapeutic use | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Benzopyrans - administration & dosage | Ethanolamines - therapeutic use | Tetrazoles - therapeutic use | Valine - therapeutic use | Aged | Tetrazoles - adverse effects | Valine - adverse effects | Drug Combinations | Hypertension | Usage | Patient outcomes | Dosage and administration | Drug therapy | Oxidative stress | Health Insurance Portability & Accountability Act 1996-US | Cardiovascular disease | Blood pressure | Drug dosages
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 374, Issue 21, pp. 2009 - 2020
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 377, Issue 9767, pp. 741 - 750
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 01/2008, Volume 48, Issue 1, pp. 85 - 95
We conducted 3 open–label, multiple–dose, 3‐period, randomized, crossover studies in healthy subjects to assess the potential pharmacokinetic interaction... 
type 2 diabetes | vildagliptin | calcium channel blocker | Dipeptidyl peptidase IV inhibitor | angiotensin converting enzyme inhibitor | pharmacokinetics | angiotensin receptor blocker | Type 2 diabetes | Angiotensin converting enzyme inhibitor | Calcium channel blocker | Vildagliptin | Angiotensin receptor blocker | Pharmacokinetics | LAF237 | RISK | PHARMACODYNAMICS | BLOOD-PRESSURE | DIABETES-MELLITUS | BIOTRANSFORMATION | MEN | PHARMACOLOGY & PHARMACY | HYPERTENSION | TYPE-2 | STAGE RENAL-DISEASE | dipeptidyl peptidase IV inhibitor | Nausea - chemically induced | Tablets | Humans | Middle Aged | Half-Life | Pyrrolidines - adverse effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Nitriles - pharmacokinetics | Ramipril - administration & dosage | Drug Interactions | Tetrazoles - administration & dosage | Ramipril - analogs & derivatives | Adamantane - administration & dosage | Ramipril - adverse effects | Amlodipine - administration & dosage | Adamantane - analogs & derivatives | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Administration, Oral | Pyrrolidines - pharmacokinetics | Amlodipine - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Cross-Over Studies | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Valine - adverse effects | Nitriles - adverse effects | Tetrazoles - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - adverse effects | Valsartan | Area Under Curve | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Antihypertensive Agents - administration & dosage | Pyrrolidines - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - pharmacokinetics | Valine - administration & dosage | Nitriles - administration & dosage | Amlodipine - pharmacokinetics | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Female | Headache - chemically induced | Adamantane - pharmacokinetics | Adamantane - adverse effects | Valine - pharmacokinetics | Valine - analogs & derivatives | Ramipril - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Tetrazoles - adverse effects | Amlodipine | Dosage and administration | Enzyme inhibitors | Research
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2013, Volume 31, Issue 4, pp. 833 - 844
The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell proliferation,... 
Medicine & Public Health | MET inhibitor | Oncology | MST1R | Pharmacology/Toxicology | LY2801653 | ROS1 | MKNK | ACTIVATION | GEFITINIB | TYROSINE KINASE | COEXPRESSION | AMPLIFICATION | ONCOLOGY | AXL | C-MET | RESISTANCE | PHARMACOLOGY & PHARMACY | GROWTH-FACTOR | MUTATIONS | Niacinamide - analogs & derivatives | Proto-Oncogene Proteins c-met - metabolism | Tetrazoles - pharmacology | Blood Vessels - pathology | Humans | Biological Availability | Antineoplastic Agents - administration & dosage | Indazoles - administration & dosage | Protein Kinase Inhibitors - chemistry | Tetrazoles - chemistry | Niacinamide - chemistry | Tetrazoles - administration & dosage | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Indazoles - chemistry | Administration, Oral | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Antineoplastic Agents - chemistry | Mutation - genetics | Receptor Protein-Tyrosine Kinases - metabolism | Niacinamide - administration & dosage | Indazoles - pharmacology | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Blood Vessels - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Niacinamide - pharmacology | Complications and side effects | Enzyme inhibitors | Physiological aspects | Genetic aspects | Cellular signal transduction | Dosage and administration | Research | Drug therapy | Cancer | Studies | Pharmaceutical sciences | Tumors | Preclinical Studies
Journal Article